WO2008112297A3 - Methods of treating cancer by interfering with igf-i receptor signaling - Google Patents

Methods of treating cancer by interfering with igf-i receptor signaling Download PDF

Info

Publication number
WO2008112297A3
WO2008112297A3 PCT/US2008/003393 US2008003393W WO2008112297A3 WO 2008112297 A3 WO2008112297 A3 WO 2008112297A3 US 2008003393 W US2008003393 W US 2008003393W WO 2008112297 A3 WO2008112297 A3 WO 2008112297A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
treating cancer
interfering
methods
receptor signaling
Prior art date
Application number
PCT/US2008/003393
Other languages
French (fr)
Other versions
WO2008112297A2 (en
Inventor
Hong Sun
Papia Ghosh
Yongsoon Kim
Original Assignee
Univ Yale
Nevada Cancer Inst
Hong Sun
Papia Ghosh
Yongsoon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Nevada Cancer Inst, Hong Sun, Papia Ghosh, Yongsoon Kim filed Critical Univ Yale
Publication of WO2008112297A2 publication Critical patent/WO2008112297A2/en
Publication of WO2008112297A3 publication Critical patent/WO2008112297A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

The invention includes methods of reducing proliferation, causing apoptosis and treating cancer through the inhibition of ASM, the disruption of lipid rafts and the interference with IGF-IR and Racl signaling using a variety of compounds including siRNA, anti-ASM antibodies, anti-ceramide antibodies, short- chain ceramide derivatives, desipramine, clomipramine, mangostin and/or sphingomyelin substrate analogues.
PCT/US2008/003393 2007-03-13 2008-03-13 Methods of treating cancer by interfering with igf-i receptor signaling WO2008112297A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90667307P 2007-03-13 2007-03-13
US60/906,673 2007-03-13

Publications (2)

Publication Number Publication Date
WO2008112297A2 WO2008112297A2 (en) 2008-09-18
WO2008112297A3 true WO2008112297A3 (en) 2008-10-30

Family

ID=39760296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003393 WO2008112297A2 (en) 2007-03-13 2008-03-13 Methods of treating cancer by interfering with igf-i receptor signaling

Country Status (1)

Country Link
WO (1) WO2008112297A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363394B2 (en) * 2010-01-19 2012-01-31 Universidad De Sevilla USE OF AMITRIPTILINE AS AN ANTITUMORAL AGENT FOR THE TREATMENT OF LUNG CANCER.
WO2012036180A1 (en) * 2010-09-16 2012-03-22 株式会社エコリソース研究所 Xanthone derivative and use thereof
CL2011000273A1 (en) 2011-02-08 2011-06-17 Univ Pontificia Catolica Chile Use of a phosphatidic acid phosphohydrolase enzyme (pap) inhibitor or combination of inhibitors, in which the inhibitor is d (+) propranolol, and the combination is racemic mixture of propranolol od (+) propranolol together with desipramine, to prepare a Useful medicine in the treatment of cancer.
CN105218507B (en) * 2015-09-30 2020-10-02 中国药科大学 1, 3, 6, 7-tetrahydroxy xanthone derivative and preparation method and application thereof
BR112023024640A2 (en) * 2021-05-27 2024-02-27 Isu Abxis Co Ltd ANTIBODY THAT SPECIFICALLY BINDS TO THE ASM PROTEIN

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228276A1 (en) * 2002-04-09 2003-12-11 Pitossi Fernando Juan Neuroprotective and neurogenerative effects of the long-term expression of TNF alpha in the substantia nigra and a new animal model for Parkinson's disease
US20040247603A1 (en) * 2000-12-22 2004-12-09 Medlyte, Inc. Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20050002865A1 (en) * 1996-10-28 2005-01-06 Amersham Health As Diagnostic/therapeutic agents
US20050209219A1 (en) * 2002-08-23 2005-09-22 Erich Gulbins Prophylaxis and treatment of infectious diseases
US20060003968A1 (en) * 2004-04-02 2006-01-05 Jeremy Green Azaindoles useful as inhibitors of rock and other protein kinases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002865A1 (en) * 1996-10-28 2005-01-06 Amersham Health As Diagnostic/therapeutic agents
US20040247603A1 (en) * 2000-12-22 2004-12-09 Medlyte, Inc. Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
US20030228276A1 (en) * 2002-04-09 2003-12-11 Pitossi Fernando Juan Neuroprotective and neurogenerative effects of the long-term expression of TNF alpha in the substantia nigra and a new animal model for Parkinson's disease
US20050209219A1 (en) * 2002-08-23 2005-09-22 Erich Gulbins Prophylaxis and treatment of infectious diseases
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20060003968A1 (en) * 2004-04-02 2006-01-05 Jeremy Green Azaindoles useful as inhibitors of rock and other protein kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMADA ET AL.: "Biological Activities of a-Mangostin Derivatives against Acidic Sphingomyelinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, pages 3151 - 3153, XP002728402, DOI: doi:10.1016/S0960-894X(03)00719-4 *
OKAMOTO ET AL.: "Inhibitory Regulation of Rac Activation, Membrane Ruffting, and Cell Migration by the G Protein-Coupled Sphingosine-1-Phosphate Receptor EDG5 but not EDG1 Or EDG3", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 24, 2000, pages 9247 - 9261, XP002951031 *

Also Published As

Publication number Publication date
WO2008112297A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008083252A3 (en) Methods of use for cyclopamine analogs
WO2007134086A3 (en) Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
MX2009012561A (en) Stevioside polymorphic and amorphous forms, methods for their formulation, and uses.
WO2012099973A3 (en) Compositions and methods for treating cancer
SG169988A1 (en) Rnai inhibition of alpha-enac expression
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
GB0812642D0 (en) Compounds
MX2011006334A (en) Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c] [1,2] oxaborol-1-ol.
MX2009008660A (en) Method for the preparation of therapeutically valuable triphenylbutene derivatives.
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
MX2010005986A (en) Grain products having a potent natural sweetener and a bulking agent.
MX339300B (en) Small molecule inhibitors of n-terminus activation of the androgen receptor.
WO2008112297A3 (en) Methods of treating cancer by interfering with igf-i receptor signaling
WO2011006035A3 (en) Bis-ketoiminate copper precursors for deposition of copper-containing films
WO2010027150A3 (en) New preparation of hydroxychloroquine
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
MX2009009490A (en) Novel prodrugs.
WO2008060693A3 (en) Tetracyclic imidazole analogs
WO2008156012A1 (en) CANCER REMEDY CONTAINING MORTALIN siRNA
AU2009235634A8 (en) Substituted sulfonamide derivatives
MX2011012022A (en) Bisazo compounds.
MX2009011787A (en) Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof.
WO2008092928A9 (en) NOVEL ß-LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF
UA34487U (en) Aquananomagnesium
WO2009147632A3 (en) New compounds for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742085

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742085

Country of ref document: EP

Kind code of ref document: A2